Contact UsInvestorsCareersMediaScienceContact Us
HomePartnershipsWorking With The NHS and other Healthcare OrganisationsCollaborative WorkingCollaborative Working Project between Guy’s and St Thomas’ NHS Foundation Trust, King’s College NHS Foundation Trust and Pfizer LimitedCollaborative Working Project between Guy’s and St Thomas’ NHS Foundation Trust, King’s College NHS Foundation Trust and Pfizer Limited
Developing and coordinating the clinical pathways to review and optimise patients with Cardiac Amyloidosis (CA)
Background
The term amyloidosis describes a group of disorders caused by abnormal folding, aggregation and accumulation of certain proteins in the tissues, in an abnormal form known as amyloid deposits. Amyloidosis is classified according to the protein that forms the amyloid fibrils, and the clinical picture and symptoms can differ greatly between one amyloid type and another. There are various types of amyloidosis. Different proteins are implicated in different types of amyloids.

The National Amyloidosis Centre (NAC) is currently the only commissioned centre in England which offers a specialised centre of excellence for patients with amyloidosis and is funded via NHS Specialised Commissioning to provide diagnosis and treatment advice for these patients. 

Many patients with suspected CA are elderly and have multiple co-morbidities, making travel to specialist centres particularly challenging. Fortunately, the development of validated clinical algorithms over the past five years has enabled the often non-invasive diagnosis of CA using investigations that are now accessible in some larger hospitals. To ensure timely diagnosis and high-quality care, there is now a clear need to develop a network of expert regional centres, where multidisciplinary teams can manage patients as close to home as possible.
Project

This project is aimed at supporting, via a collaborative working agreement between Guy’s and St Thomas’ NHS Foundation Trust, King’s College NHS Foundation Trust and Pfizer, the delivery of a Clinical Nurse Specialist and Administrator support to facilitate and coordinate amyloidosis services across the South London area. This approach aims to ensure that there is a thorough and coordinated clinical pathway for patients with either suspected or confirmed CA to access local multidisciplinary team/s and specialist diagnostics. Ensuring timely access to approved treatments and follow-up care under the guidance of specialist clinicians.

Benefits
Benefits to patients
  • Improved access to specialised diagnostics, clinics and treatments.
  • Coordinated patient pathway for CA.
  • Improve adherence to medicines through specialist nurse support.
  • Supporting improved outcomes for CA patients (e.g. improve decision making by specialist multi-disciplinary team (MDT), access to expert diagnostics and experience in treatment decision making).
  • Reduced variation between Trusts across the network for all CA patients entering the clinical pathway.

Benefits to the NHS
  • Increased cross trust collaboration.
  • Improved clinical pathways.
  • Earlier diagnosis and treatment with associated improved clinical outcomes - reducing hospital attendances/admissions in the long term.
  • Reducing patient waiting times.
  • Improved access to diagnostics.

Benefits to Pfizer
  • The project will result in the identification of patients who are eligible for approved Pfizer treatments.
  • Improved access to diagnostics.
  • Increase understanding of service provision and pathway design across multiple trusts.
Potential Outcomes
  • Coordinated Amyloid clinics and MDTs across South London.
  • Improved patient management and continuity of care.
Proposed Term of the Collaborative Working Project
Planned start date: 1st December 2025.
Planned end date: 1st December 2026.
Resource Allocation
Pfizer Ltd will contribute:
  • Funding:
    • Clinical Nurse Specialist (CNS) Band 8 mid and band 5 Data Administrator mid: £142,674.00
  • Human resource: 135 hours (£6,075.00)
  • Total transfer of value: £148,749.00*

*This is calculated as the sum of the direct financial contribution by Pfizer PLUS the benefit in kind value of the human resources provided by Pfizer


Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust will contribute:
  • Diagnostics: £92,750.00
  • Human resource: 960 hours (£48,000.00)
  • Total: £140,750.00
ResponsibilityHealthcare Organisation Grants

Pfizer is committed to being transparent about the relationships we have with other organisations. 

PartnershipsDonations and Grants

Find out about the donations and grants we make available to support healthcare, scientific research and education.

PP-UNP-GBR-13376 / November 2025
Science Products Responsibility Partnerships Careers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2025 Pfizer Limited. PP-UNP-GBR-13382  / September 2025. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427.  This website is intended for the general public in the UK.